INDICATIONS
CONTRA-INDICATIONS
DOSAGE
SIDE-EFFECTS
PREGNANCY
OVERDOSE
IDENTIFICATION
PATIENT INFORMATION
FLAMAZINE* CREAM
SCHEDULING STATUS:
Schedule 4
PROPRIETARY NAME
(and dosage form):
FLAMAZINE* CREAM
COMPOSITION:
A white hydrophilic cream containing silver sulphadiazine 0,01 g/gram of cream. Sterile if unopened.
PHARMACOLOGICAL CLASSIFICATION:
A 14.2 Wound dressing
PHARMACOLOGICAL ACTION:
As silver sulphadiazine is relatively insoluble, it reacts very slowly with the chloride and protein components of tissue exudate to form silver chloride, silver protein complexes and sodium sulphadiazine. The mechanisms for silver ion release are complex, but silver chloride is very slightly soluble and slowly releases silver ions, which are then free to exert their bactericidal effect. These silver ions are thought to be reversibly adsorbed by bacterial cells by association with SH groups or histidine residues in the bacterial protein of the transport system across the cell wall.
NaCl + AgSd –––––––> AgCl + NaSd
AgCl ========= Ag+ + Cl¯
AgCl + NaCl ========= Na+ + AgCl¯2
Thus silver sulphadiazine acts as a sustained release depot of silver and sulphadiazine at the wound surface. This slow liberation of silver does not cause the rapid and extensive depletion of chloride ion experienced when silver nitrate solutions are used and thus electrolyte disturbance is minimised.
INDICATIONS:
FLAMAZINE is a topical antibacterial agent for the prevention and treatment of burn wound infections caused by Gram negative organisms such as Pseudomonas aeruginosa and Candida albicans.. FLAMAZINE can also be used for the treatment of leg ulcers and pressure sores
CONTRA-INDICATIONS:
Hypersensitivity to sulphonamide. Because sulphonamide therapy is known to increase the possibility of kernicterus, silver sulphadiazine cream should not be used in pregnant women at term, in premature infants or in infants during the first months of life. FLAMAZINE should not be used if hepatic and renal function become impaired or if the condition of porphyria is suspected.
WARNINGS:
FOR EXTERNAL USE ONLY.
The safety of FLAMAZINE in pregnancy and lactation has not been established. A fall in white blood cell count has been demonstrated, but is not thought to be associated with the treatment used and probably reflects the condition of the burned patient.
DOSAGE AND DIRECTIONS FOR USE:
FLAMAZINE should be applied daily in a layer approximately 3 - 5 mm thick with a sterile gloved hand or spatula. The wound may be dressed or left open. One container of FLAMAZINE should be reserved for one patient and any remaining cream should be discarded on completion of treatment.
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Patients should be watched carefully for sensitivity reactions; the separation of the eschar may be delayed and fungal invasion of the wound may occur. Local skin sensitivity to FLAMAZINE may occur, especially when exposed to sunlight. Appreciable amounts of sulphadiazine may be absorbed systemically to produce therapeutic blood levels, and particular attention must be paid to adequate fluid intake and acid base balances.
IDENTIFICATION:
A white to off-white cream.
PRESENTATION:
FLAMAZINE is available in 500 g and 250 g jars and in tubes of 50 g.
STORAGE INSTRUCTIONS:
Store below 25°C protected from light.
KEEP OUT OF REACH OF CHILDREN
REGISTRATION NUMBER:
H/14.2/3003
NAME AND BUSINESS ADDRESS OF APPLICANT:
Smith & Nephew Pharmaceuticals (Pty) Limited,
30 Gillitts Road, Pinetown 3610
DATE OF PUBLICATION OF THIS PACKAGE INSERT:
September 2000
* Trademark of Smith & Nephew.
1840 0517
Updated on this site: April 2005
Source: Hospital Pharmacy
SAEPI HOME PAGE
TRADE NAME INDEX
GENERIC NAME INDEX
FEEDBACK
Information presented by Malahyde Information Systems © Copyright 1996-2005